World / Cancer

World Cancer Declaration Sets Ambitious Targets For 2020

World Cancer Declaration Sets Ambitious Targets For 2020

Time 02.09.2008 06:16 Source  medicalnewstoday.com

A summit of more than 60 high-level policymakers, leaders and health experts have adopted a global plan aimed at tackling the growing cancer crisis in developing countries. The plan, contained in the World Cancer Declaration, recommends a set of 11 cancer-busting targets for 2020 and outlines priority steps that need to be taken in order to meet them.

Region World Category Cancer
New Approach To Treating Endometrial Cancer Discovered By TGen And Washington University Researchers

New Approach To Treating Endometrial Cancer Discovered By TGen And Washington University Researchers

Time 02.09.2008 04:16 Source  medicalnewstoday.com

Researchers at the Translational Genomics Research Institute (TGen) has announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells. In a potentially major breakthrough, TGen scientists and collaborators at Washington University School of Medicine in St.

Region World Category Cancer
Landmark Study Opens Door To New Cancer, Aging Treatments

Landmark Study Opens Door To New Cancer, Aging Treatments

Time 02.09.2008 04:16 Source  medicalnewstoday.com

Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies. Researchers have attempted for more than a decade to find drugs that shut down telomerase widely considered the No.

Region World Category Cancer
REVLIMID(R) Demonstrates Activity Against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

REVLIMID(R) Demonstrates Activity Against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Time 02.09.2008 04:16 Source  medicalnewstoday.com

Celgene International Sàrl (Nasdaq:CELG) announced the publication of peer-reviewed data from a Phase II study of REVLIMID in relapsed or refractory aggressive non-Hodgkin's lymphoma in the Journal of Clinical Oncology. According to the data, REVLIMID, as an oral monotherapy, demonstrated activity in patients at an advanced stage of the disease who had received a median of four prior treatments and had limited treatment options.

Region World Category Cancer
« Previous 0 Next »
« September 2008 »
SunMonTueWedThuFriSat
 010203040506
07080910111213
14151617181920
21222324252627
282930 

Date: 22 November 2008 - 06:05

Number of sources in English: 130